share_log

復宏漢霖:自願公告 - HLX22(抗人表皮生長因子受體-2(HER2)人源化單克隆抗體注射液)聯合曲妥珠單抗和化療或聯合德曲妥珠單抗治療HER2表達實體瘤的2期臨床試驗申請獲國家藥品監督管理局批准

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE 2 CLINICAL TRIAL OF HLX22(ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)HUMANISED MONOCLONAL ANTIBODY INJECTION)IN COMBINATION WITH TRASTUZUMABAND CHEMOTHERAPY OR HLX22 IN COMBINATIONWITH TRASTUZUMAB

HKEX ·  Dec 4, 2024 18:08
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more